Vipul Devas
About Vipul Devas
Vipul Devas is the Director of Global Biometrics and Data Science at Bristol Myers Squibb with over 20 years of experience in the pharmaceutical and biotechnology industry.
Current Role at Bristol Myers Squibb
Vipul Devas currently holds the position of Director, Global Biometrics and Data Science at Bristol Myers Squibb in the United States. In this leadership role, he oversees biostatistics and data science initiatives that support the company's global biometrics functions. His work includes guiding data-driven decision-making processes and ensuring compliance with regulatory standards.
Past Experience at Syneos Health
Vipul Devas previously served as Senior Director of Biostatistics at Syneos Health from 2011 to 2021 in the United States. During his 10-year tenure, he led multiple biostatistics projects and contributed to various clinical trials. His expertise in biostatistics played a key role in the development of clinical strategies and the execution of data analysis protocols.
Leadership Roles at Novartis
Vipul Devas has extensive experience at Novartis, where he held significant leadership roles. As Global Project Lead from 2010 to 2011 in the USA, he managed cross-functional teams to support global projects. Prior to that, he was the Group Head from 2007 to 2009, working across India and the USA. In these roles, he was instrumental in steering global initiatives and fostering collaboration among international teams.
Academic Background and PhD in Statistics
Vipul Devas earned his Doctor of Philosophy (PhD) in Statistics from the Fox School of Business at Temple University. His academic background provides a strong foundation in statistical methodologies, which he has applied throughout his career in the pharmaceutical and biotechnology industry.
Experience at GSK and Contributions
From 2001 to 2007, Vipul Devas worked as a Principal Statistician at GlaxoSmithKline (GSK) in Collegeville, Pennsylvania. Here, he was involved in various aspects of statistical analysis and contributed significantly to the regulatory submissions and interactions with health authorities. His work supported the approval of multiple pharmaceutical products, showcasing his expertise in biostatistics.